Oncobit has closed a successful seed financing round, details of which can be found in a press release. In total, the start-up secured investment totaling 2.3 million Swiss francs, with the Zug-based GF Group Holding AG and the Basel-based Avanteca Partners AG, among others, included in the group of investors.
Oncobit was founded as a spin-off from the University of Zurich. The company develops highly sensitive diagnostic and monitoring tests for cancer patients. These aim to facilitate personalized treatment approaches. At present, Oncobit is focused on skin cancer patients, although the company’s approach is to be further developed and applied to other cancer indications in the future. Oncobit intends to initially use this fresh capital to expand its team and prepare its products for market launch.
Following the investment, Christian Schilling from Avanteca Partners will join the Board of Directors of Oncobit. In addition, the diagnostic expert Daniel Schöner will also be taking a seat on the board. Ruedi Gygax, the former CEO of Novartis Venture Fund, has been named as the new Chairman of the Board of Directors.
Claudia Scheckel, CEO of Oncobit, welcomes the investment and the new board members, who she says will contribute the requisite industry expertise to bring Oncobit “to the forefront of precision medicine”.